Search Results - Asnis-Alibozek, Aviva

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

    Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients by Yorio, Jeffrey Thomas, Asnis-Alibozek, Aviva G, Kasturi, Vijay, Hutson, Thomas E

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    The unmet need for rapid epileptic seizure termination (REST)

    The unmet need for rapid epileptic seizure termination (REST) by Asnis-Alibozek, Aviva, Detyniecki, Kamil

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

    Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial by Beckermann, Kathryn E, Asnis-Alibozek, Aviva G, Atkins, Michael B, Escudier, Bernard, Hutson, Thomas E, Kasturi, Vijay, McDermott, David F, Pal, Sumanta K, Porta, Camillo, Rini, Brian I, Verzoni, Elena

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    A Review of Contemporary Data on Surgically Resected Renal Masses—Benign or Malignant?

    A Review of Contemporary Data on Surgically Resected Renal Masses—Benign or Malignant? by Corcoran, Anthony T, Russo, Paul, Lowrance, William T, Asnis-Alibozek, Aviva, Libertino, John A, Pryma, Daniel A, Divgi, Chaitanya R, Uzzo, Robert G

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4‑Hydroxy‑N,N‑diisopropyltryptamine

    RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4‑Hydroxy‑N,N‑diisopropyltryptamine by Bryson, Nathan, Alexander, Robert, Asnis-Alibozek, Aviva, Ehlers, Michael D.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  6. 6
    Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

    Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial by Barata, Pedro C, Chehrazi-Raffle, Alexander, Allman, Kimberly D, Asnis-Alibozek, Aviva, Kasturi, Vijay, Pal, Sumanta K

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  7. 7
    The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma

    The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma by Love, Neil, Lonial, Sagar, Ziel, Kathryn, Paley, Douglas, Elder, Melanie, Asnis-Alibozek, Aviva

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

    Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients by Yorio, Jeffrey Thomas, Asnis-Alibozek, Aviva G, Kasturi, Vijay, Hutson, Thomas E

    Get full text
    Report
    Save to List
    Saved in:
  9. 9
    Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

    Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients by Yorio, Jeffrey Thomas, Asnis-Alibozek, Aviva G, Kasturi, Vijay, Hutson, Thomas E

    Get full text
    Report
    Save to List
    Saved in:
  10. 10
    Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

    Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial by Barata, Pedro C, Chehrazi-Raffle, Alexander, Allman, Kimberly D, Asnis-Alibozek, Aviva, Kasturi, Vijay, Pal, Sumanta K

    Published in The Oncologist
    Get full text
    Report
    Save to List
    Saved in:
  11. 11
    Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

    Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial by Beckermann, Kathryn E, Asnis-Alibozek, Aviva G, Atkins, Michael B, Escudier, Bernard, Hutson, Thomas E, Kasturi, Vijay, McDermott, David F, Pal, Sumanta K, Porta, Camillo, Rim, Brian I, Verzoni, Elena

    Published in The Oncologist
    Get full text
    Report
    Save to List
    Saved in:
  12. 12
    Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

    Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial by Beckermann, Kathryn E, Asnis-Alibozek, Aviva G, Atkins, Michael B, Escudier, Bernard, Hutson, Thomas E, Kasturi, Vijay, McDermott, David F, Pal, Sumanta K, Porta, Camillo, Rim, Brian I, Verzoni, Elena

    Published in The Oncologist
    Get full text
    Report
    Save to List
    Saved in:

Search Tools: